Prostate Cancer

The phase 2 study explored the investigational agent BXCL701 in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer.

“I think this study gives us actual numbers, so we can have a sense of how much time people will take off over time,” says Samuel L. Washington, MD, MAS.

"A lot of patients with prostate cancer are going to receive one of these agents," says Tanya B. Dorff, MD.

"It's not just teaching all about prostate cancer; it's real life and how people are experiencing prostate cancer," says David F. Mobley, MD.

Dr. Amir H. Lebastchi reviews retrospective data comparing software-based and cognitive-based fusion biopsy approaches, providing valuable insights into the findings.

Amir H. Lebastchi, MD, explores the evolving landscape in the context of fusion-guided prostate biopsy methods.

In the second article of the series, Paul Sieber, MD, shares best practices for the administration of leuprolide in patients with advanced/metastatic prostate cancer.

“There are always other aspects of care other than that immediate treatment period that's needed,” says Samuel L. Washington III, MD.

Patients who underwent treatment with SBRT demonstrated a 5-year disease control rate of 96%, compared with 95% among patients who underwent conventionally fractionated radiation therapy.

In the first article of this series, Benjamin H. Lowentritt, MD, FACS, gives an overview of micronized abiraterone and its role in the treatment of patients with metastatic castrate-resistant prostate cancer.

In the second interview of the series, Paul Sieber, MD, provides expert insights on the management of adverse effects seen in patients receiving leuprolide for the treatment of advanced/metastatic prostate cancer.

Dr Amir H. Lebastchi delves into the latest advancements and evolving tactics in the field of prostate cancer biopsy and diagnostic procedures.

Amir H. Lebastchi, MD, provides insights into the current prostate cancer landscape, emphasizing the importance of prostate cancer screening and early detection.

Experts Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, consider the continued impact of PSMA PET imaging on prostate cancer management and emerging modalities that could revolutionize patient care.

"I think what should be more appropriate is that the initial treatment decision does not impact [survival], but I don't think you can say that intervening aggressively for this lethal disease does not alter the course," says Isaac Y. Kim, MD, PhD, MBA.

The PSE test was shown to improve the predictive accuracy of a standard PSA test from 55% to 94%.

In the first article of this series, Naveen Kella, MD, discusses the transformative impact of PSMA PET-CT imaging on prostate cancer diagnosis, highlighting its advantages and addressing clinical challenges and guidelines in this evolving field.

“I've always felt like my patients are my partners in discovery,” says Edward M. Schaeffer, MD, PhD.

The addition of SBRT to upfront abiraterone acetate and prednisone (AAP) reduced the risk of disease progression or death by 65% compared with AAP alone in patients with oligometastatic castration-resistant prostate cancer.

“[These] results imply that prostate cancer survival could be improved, especially in historically under-served groups, by improving the timeliness of access to medical care," says Sean Clouston, PhD.

“With regards to urinary function, there were actually no differences between the 2 eras. We thought that was a little surprising,” says Udit Singhal, MD.

UCSF is West Coast leader for the innovative, minimally invasive treatment for prostate cancer patients.

Paul M. Yonover, MD, FACS, offers closing thoughts on unmet needs and clinical challenges surrounding the treatment of prostate cancer.